Last reviewed · How we verify
NCT05942794
Identification of Oral Lesions Through an Autofluorescence System
NA trial testing Screening examination in Oral Leukoplakia in 200 participants. Status unknown.
1 March 2024
Quick facts
| Lead sponsor | Federico II University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 200 |
| Start date | 1 June 2023 |
| Primary completion | 1 March 2024 |
| Estimated completion | 1 October 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Screening examination
Conditions studied
- Oral Leukoplakia — all drugs for Oral Leukoplakia →
- Autofluorescence — all drugs for Autofluorescence →
- Secondary Prevention — all drugs for Secondary Prevention →
- Keratosis — all drugs for Keratosis →
Sponsor
Federico II University
Who can join
Adults 18 to 70, any sex, with Oral Leukoplakia or Autofluorescence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study will be to evaluate the efficacy of a tissue autofluorescence detection system as an aid to clinical screening in identifying lesions of the oral mucosa. The screening process will be performed by 3 clinicians with a different level of experience. Sensitivity and specificity tests will be conducted.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05942794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Oral Leukoplakia
Currently open trials in the same condition.
- NCT07331935 — Efficacy of Topical Coenzyme Q10 and Curcumin for Oral Leukoplakia Treatment · NA · recruiting
- NCT07149220 — Fenretinide Mucoadhesive Patch: Evaluation of Oral Cancer Prevention Efficacy in Adults With Premalignant Oral Lesions. · Phase 1 · recruiting
- NCT05727761 — Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia · Phase 2 · recruiting
- NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
- NCT03975322 — Prediction of Malignant Transformation of Oral Leukoplakia Using a MAGE-A-based Immunoscore · recruiting
Other Federico II University trials
Trials by the same sponsor.
- NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
- NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
- NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
- NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
- NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05942794 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Federico II University
- Last refreshed: 28 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05942794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing